Cite
MLA Citation
A. Kavanaugh et al.. “OP0078 Apremilast, an Oral Phosphodiesterase 4 Inhibitor, is Associated with Long-Term (52-WEEK) Improvement in Measures of Disease Activity in Patients with Psoriatic Arthritis: Results from 3 Phase 3, Randomized, Controlled Trials.” Annals of the rheumatic diseases, vol. 73, 2014, pp. 90–91. http://access.bl.uk/ark:/81055/vdc_100135148040.0x00005c